FSCN1 and neoplasm: Two ongoing clinical trials (Clinical Trials: NCT05023486; EudraCT: 2021-001328-17), in which fascin inhibitors are being tested to treat different tumours, including breast cancer, will provide novel insights about mechanisms of reverting chemoresistance [135].